Affimed N.V. (AFMD) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 11/03/21
Affimed to Report Third Quarter 2021 Financial Results & Corporate Update on November 10, 2021GlobeNewsWire • 10/29/21
Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at the 36th Annual Meeting of the Society for Immunotherapy of CancerGlobeNewsWire • 10/01/21
Affimed N.V. (AFMD) CEO Adi Hoess on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 09/08/21
Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational ProgressGlobeNewsWire • 09/08/21
Affimed to Report Second Quarter 2021 Financial Results & Corporate Update on September 8, 2021GlobeNewsWire • 08/23/21
Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing TumorsGlobeNewsWire • 07/30/21
Affimed N.V. (AFMD) CEO Adi Hoess on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/01/21
Affimed Reports First Quarter 2021 Financial Results and Highlights Operational ProgressGlobeNewsWire • 07/01/21
Affimed to Report First Quarter 2021 Financial Results & Corporate Update July 1, 2021GlobeNewsWire • 06/22/21
Affimed's AFM13 In Combination With NK Cells Show Improved Tumor Recognition, Killing In Preclinical StudiesBenzinga • 05/14/21
Affimed Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of AFM13 in Combination with Natural Killer CellsGlobeNewsWire • 05/13/21